Research Core
研究核心
基本信息
- 批准号:8355944
- 负责人:
- 金额:$ 16.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-16 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntineoplastic AgentsAreaBreast Cancer TreatmentCancer Research InfrastructureChemicalsCollaborationsCommunity ServicesEducational workshopEquipmentFacultyFederal GovernmentFloridaFundingFunding OpportunitiesGoalsGrantHistorically Black Colleges and UniversitiesLeadMainstreamingMalignant NeoplasmsMalignant neoplasm of lungMinorityMolecularOutcomePopulationProductivityPublishingResearchResearch InfrastructureResearch PersonnelResearch TrainingResourcesTherapeutic StudiesUniversitiesWritinganticancer researchcancer therapychemotherapeutic agentinnovationinvestigator trainingmalignant breast neoplasmtumor
项目摘要
The overall goal of this initiative is to strengthen the research infrastructure for cancer research at Florida A&M University through research collaboration in a focused and coordinated effort. Despite significant discovery of chemotherapeutic agents and their mechanisms of action, the need for new chemical entities having new mechanisms of action for the treatment of breast and lung cancer remains high. Therefore, an aggressive exploitation of new anticancer agents/combination and their molecular mechanisms involved in tumor regression are planned through research collaboration. Breast and lung cancer are the most common cancer affecting minority populations and these two cancers hence been chosen to be pursued at FAMU.
Furthermore, FAMU has researchers who are performing cutting edge research in these areas and hence can contribute in building a strong infrastructure for other researchers. Another impetus for this activity is to take a step towards remedy for the persistent disparity in the number of minority investigators involved in targeted cancer therapy research. The difficulty in implementing innovative approaches in cancer research at historically
black colleges and universities is due to the lack of adequate resources, trained investigators and research infrastructure for breast and lung cancer therapy.
该计划的总体目标是通过集中和协调的研究合作,加强佛罗里达A&M大学癌症研究的研究基础设施。尽管化学治疗剂及其作用机制有了重大发现,但对用于治疗乳腺癌和肺癌的具有新作用机制的新化学实体的需求仍然很高。因此,计划通过研究合作积极开发新的抗癌药物/组合及其参与肿瘤消退的分子机制。乳腺癌和肺癌是影响少数民族人口的最常见癌症,因此选择这两种癌症在FAMU进行研究。
此外,FAMU拥有在这些领域进行尖端研究的研究人员,因此可以为其他研究人员建立强大的基础设施做出贡献。这项活动的另一个推动力是采取措施,弥补参与有针对性的癌症治疗研究的少数民族研究人员人数持续不均衡的问题。在历史上,在癌症研究中实施创新方法的困难
黑人学院和大学的主要原因是缺乏足够的资源、训练有素的调查人员和乳腺癌和肺癌治疗的研究基础设施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mandip Singh Sachdeva其他文献
Mandip Singh Sachdeva的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mandip Singh Sachdeva', 18)}}的其他基金
Exosomal Based micro RNA delivery for Resistant Lung Cancer
基于外泌体的 micro RNA 递送治疗耐药性肺癌
- 批准号:
10629892 - 财政年份:2023
- 资助金额:
$ 16.48万 - 项目类别:
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles
替米沙坦对靶向纳米颗粒肿瘤内分布的作用
- 批准号:
8791884 - 财政年份:2014
- 资助金额:
$ 16.48万 - 项目类别:
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles
替米沙坦对靶向纳米颗粒肿瘤内分布的作用
- 批准号:
8637758 - 财政年份:2014
- 资助金额:
$ 16.48万 - 项目类别:
Targeted Nanocarrier Combination Based Therapy for Lung Cancer
靶向纳米载体组合治疗肺癌
- 批准号:
8552025 - 财政年份:2013
- 资助金额:
$ 16.48万 - 项目类别:
Targeted Nanocarrier Combination Based Therapy for Lung Cancer
靶向纳米载体组合治疗肺癌
- 批准号:
8355084 - 财政年份:2012
- 资助金额:
$ 16.48万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8018928 - 财政年份:2011
- 资助金额:
$ 16.48万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8537387 - 财政年份:2011
- 资助金额:
$ 16.48万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8321434 - 财政年份:2011
- 资助金额:
$ 16.48万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 16.48万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 16.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 16.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 16.48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 16.48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 16.48万 - 项目类别: